ReviewMolecular genetics and genomics : MGG2025
Overview of high mobility group box 3 (HMGB3] protein.
Review in Molecular genetics and genomics : MGG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrative analysis of HMGB3 in esophageal carcinoma: expression profile, prognostic significance, and immune microenvironment associations.Translational cancer research · 2026Article
- HMGB3: A pivotal orchestrator of therapy resistance and cancer stemness in human malignancies (Review).Oncology reports · 2026Review
- Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in PediatricInternational journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High mobility group (HMG) proteins, the second most abundant chromatin proteins after histones, play essential roles in eukaryotic gene regulation. Among these, High Mobility Group Box 3 (HMGB3) is critical for DNA repair and has gained prominence in cancer biology due to its involvement in tumorigenesis and cancer progression. This study explores the cellular and molecular mechanisms underlying HMGB3's oncogenic functions, with a focus on its potential as a prognostic biomarker and therapeutic target. We highlight that HMGB3 is frequently overexpressed in tumor tissues and discuss its association with poor clinical outcomes. Furthermore, we examine the ceRNA network and other regulatory pathways influencing HMGB3 expression, emphasizing their implications for RNA-based therapies. By comprehensively reviewing HMGB3's role across multiple cancer types, this work provides insights into novel strategies for targeting HMGB3 to improve cancer treatment efficacy. Our findings underscore the therapeutic potential of modulating HMGB3 expression and pave the way for future research into precision oncology approaches.
Indexed as
Identifiers
40498374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.